Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy
© 2020 Peripheral Nerve Society..
Diabetic peripheral neuropathy (DPN) is one of the most widespread and disabling neurological conditions, accounting for half of all neuropathy cases worldwide. Despite its high prevalence, no approved disease modifying therapies exist. There is now a growing body of evidence that DPN secondary to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) represents different disease processes, with T2DM DPN best understood within the context of metabolic syndrome rather than hyperglycemia. In this review, we highlight currently understood mechanisms of DPN, along with their corresponding potential therapeutic targets. We frame this discussion within a practical overview of how the field evolved from initial human observations to murine pathomechanistic and therapeutic models into ongoing and human clinical trials, with particular emphasis on T2DM DPN and metabolic syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Journal of the peripheral nervous system : JPNS - 25(2020), 2 vom: 24. Juni, Seite 76-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stino, Amro M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetic peripheral neuropathy |
|---|
| Anmerkungen: |
Date Completed 01.06.2021 Date Revised 02.06.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/jns.12387 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309948614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309948614 | ||
| 003 | DE-627 | ||
| 005 | 20231225135030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jns.12387 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM309948614 | ||
| 035 | |a (NLM)32412144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stino, Amro M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2021 | ||
| 500 | |a Date Revised 02.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Peripheral Nerve Society. | ||
| 520 | |a Diabetic peripheral neuropathy (DPN) is one of the most widespread and disabling neurological conditions, accounting for half of all neuropathy cases worldwide. Despite its high prevalence, no approved disease modifying therapies exist. There is now a growing body of evidence that DPN secondary to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) represents different disease processes, with T2DM DPN best understood within the context of metabolic syndrome rather than hyperglycemia. In this review, we highlight currently understood mechanisms of DPN, along with their corresponding potential therapeutic targets. We frame this discussion within a practical overview of how the field evolved from initial human observations to murine pathomechanistic and therapeutic models into ongoing and human clinical trials, with particular emphasis on T2DM DPN and metabolic syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a diabetic peripheral neuropathy | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 4 | |a modern concepts | |
| 650 | 4 | |a novel therapy | |
| 650 | 4 | |a pathophysiology | |
| 700 | 1 | |a Rumora, Amy E |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Bhumsoo |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Eva L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the peripheral nervous system : JPNS |d 1996 |g 25(2020), 2 vom: 24. Juni, Seite 76-84 |w (DE-627)NLM096439173 |x 1529-8027 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:2 |g day:24 |g month:06 |g pages:76-84 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jns.12387 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 2 |b 24 |c 06 |h 76-84 | ||